Usamos cookies para personalizar el contenido y los avisos, brindar características de redes sociales y analizar nuestro tráfico. Si continúa utilizando nuestro sitio, usted acepta nuestro uso de cookies. Avisos y exenciones de responsabilidad.

cerrar
cerrar
ir a la página de inicio.
callLlamar
Buscar
Menú
ir a la página de inicio.
1-800-432-6837 English Carreras Para Profesionales Médicos Donaciones Contáctenos
1-800-432-6837
Haga una Cita
  • Servicios Médicos
    Instituto del Cerebro Cáncer y Trastornos de la Sangre Instituto del Corazón Ortopedia y Columna Vertebral Programas Ver todos los servicios médicos
    Instituto del Cerebro Inicio
    Trastornos del Sistema Nervioso Infantiles
    Programas y Servicios Especializados
    Diagnósticos y Tratamientos
    Noticias
    Conozca al Equipo
    Historias de Pacientes
    Eventos
    Videos
    Solicite una Cita
    Cáncer y Trastornos de la Sangre Inicio
    Condiciones que Tratamos
    Programas y Servicios Integrales
    Servicios del Instituto de Cáncer
    Servicios y Programas de Apoyo
    Investigación e Informes
    Noticias y Recursos
    Videos
    Historias Pacientes
    Solicite una Cita
    Instituto del Corazón Inicio
    Condiciones que Tratamos
    Exámenes y Diagnósticos
    Programas y Servicios Integrales
    Técnicas Cardíacas Avanzadas
    Exámenes de Electrocardiogramas Gratuitos
    Estadísticas de Cirugías Cardíacas en Tiempo Real
    Noticias
    Videos
    Conozca al Equipo
    Historias de Pacientes
    Solicite una Cita
    Ortopedia y Columna Vertebral Inicio
    Condiciones que Tratamos
    Programas y Servicios Integrales
    EOS (Imágenes en 3D de Baja Radiación)
    Noticias
    Videos
    Conozca al Equipo
    Historias de Pacientes
    Solicite una Cita
    Clínicas & Programas Inicio
    Centro para el Síndrome de Beckwith-Wiedemann (SBW)
    Centro Colorrectal
    Centro de Tratamiento de la Diabetes
    Programa de Problemas de Alimentación
    Centro Integral de Epilepsia
    Programa del Dolor de Cabeza
    Centro de Enfermedad Inflamatoria del Intestino
    Programa de Leucemia y Linfoma
    Programa Neuromuscular y de Trastornos del Movimiento
    Nutritición
    Centro de Trastornos del Sueño
    Salud Deportiva
  • Ubicaciones

    La red de Nicklaus Children’s incluye varios centros de cuidados urgentes y de atención pediátrica en Miami y el sur de la Florida, incluyendo cuidado virtual.

    Ver todas las ubicaciones
    Cuidados Urgentes

    Cuidado rápido y conveniente para lesiones y enfermedades menores, sin necesidad de cita.

    Cuidados Primarios

    Pediatras certificados proveen cuidado primario apoyando la salud infantil.

    Cuidados Especializados

    Consultas con subespecialistas pediátricos cada vez más cerca de usted.

    Centros Ambulatorios

    El rango complete de servicios médicos bajo un solo techo.

    Cuidado Virtual

    Conéctese con proveedores desde la comodidad de su hogar.

  • Encuentre un Doctor

    Con más de 800 profesionales de salud, puede encontrar al especialista que necesita en nuestro directorio.

    Buscar un especialista pediátrico
    Especialidades Destacadas
    Hematología/Oncología
    Neurocirugía
    Cirugía de la Columna Vertebral
    Cardiología
    Medicina del Deporte
    Pediatría General
  • Condiciones que Tratamos

    Contamos con la experiencia necesaria para apoyar a las familias y tratar a niños afectados en cientos de enfermedades.

    Ver todas las condiciones que tratamos
    Evaluar sus síntomas
    Buscar condiciones por nombre:
    A B C D E F G H I J
    K
    L M N O P Q R S T U V
    W
    X
    Y
    Z
  • Tratamientos

    Ofrecemos lo último en tecnología de diagnósticos, incluyendo tratamientos y procedimientos de vanguardia.

    Ver todos los tratamientos que ofrecemos
    Evaluar sus síntomas
    Buscar tratamientos por nombre:
    A B C D E F G H I
    J
    K
    L M N O P Q R S T U V
    W
    X
    Y Z
  • Recursos para Pacientes
    Recursos para Pacientes
    Seguros Aceptados Pague su Cuenta Portal de Pacientes Servicios Financieros
    En su Visita a Nicklaus Children's
    Planeando Su Visita
    Mapas
    Registración Rápida
    Cuidado Centrado en la Familia
    Pacientes Internacionales: Salud Global
    Información de Salud
    Podcast
    Blog para las Familias
    Información de Salud
    SAFE KIDS Miami Dade
    Eventos Comunitarios
    Recursos Adicionales
    Registros Médicos
    Servicios financieros
    Aplicaciones para su Móvil
    Servicios Lingüísticos
    HIPAA
    Seguros Aceptados Pague su Cuenta Portal de Pacientes Servicios Financieros
  • Sobre Nosotros
    Sobre Nosotros
    Atención de Calidad
    Nuestra Misión, Visión, y Valores
    Puntos de Interés
    Historia
    Conformidad Corporativa y Auditoría Interna
    Procesos de Mejoramiento
    Liderazgo
    Junta Directiva
    Administrative Fellowship
    Liderazgo Administrativo
    Comité Médico Ejecutivo
    Sistema de Salud
    Nicklaus Children's Health System
    Nicklaus Children's Hospital Foundation
    Especialistas Pediátricos
    Nicklaus Children's Pediatric Virtual Care
    Our Healthcare Partners
    Nuestra Comunidad
    Historias de Pacientes
    Educación Médica
    Noticias y Eventos
    Directorio Telefónico
    Torre Quirúrgica Kenneth C. Griffin
    Voluntarios y Servicio Comunitario
  • Haga una Cita
  • English Carreras Para Profesionales Médicos Donaciones Contáctenos
Servicios Médicos ► Ensayos Clínicos Abiertos ► ONC23127 (CONNECT2108)
  • Instituto de Investigación (Inicio)
  • Programa de protección de sujetos humanos
  • Conozca al Equipo
  • Latest News
  • Ensayos Clínicos Abiertos
  • FAQ

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Study Details

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma

Study ID:

ONC23127 (CONNECT2108)

Study Description

MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.

Eligibility Requirements

Inclusion Criteria

  1. Age: Patients must be ≥ 12 months and ≤ 25 years of age at the time of study enrollment.
  2. Diagnosis: Patients with histologically-confirmed adamantinomatous craniopharyngioma (ACP) Histologic confirmation of ACP may be made on solid tumor or, if no solid tumor can be safely obtained, cyst fluid with classic ACP characteristics of thick, cholesterol-rich, greenish-brown liquid in the context of imaging features consistent with craniopharyngioma, including lobulated, cystic/solid mass with calcifications that originates in the sellar/suprasellar region.
  3. Disease Status: Patients must have measurable disease.
    • Stratum 1: Patients with progressive or recurrent ACP who demonstrate cystic and/or solid recurrence or progression at least 6 months post completion of radiation therapy
    • Stratum 2: Patients with measurable ACP who have undergone surgery but have NOT previously undergone irradiation (but may have received prior systemic or intracystic therapy). Progressive disease is allowed but not required.
  4. Performance Level: Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Note: Neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  5. Prior Therapy: Patients must have recovered or stabilized from the acute toxic effects of prior treatments
    • Biologic (anti-neoplastic agent): At least 7 days must have elapsed after the last (systemic or intracystic) dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair
    • Immunotherapy: At least 42 days after the completion of any type of systemic immunotherapy, e.g. tumor vaccines.
    • Monoclonal antibodies: At least 21 days after the last dose of a monoclonal antibody.
    • Radiation therapy: Patients must have had their last (conventional or hypofractionated) fraction of: a) Focal irradiation > 6 months prior to enrollment and b) No prior craniospinal irradiation is permitted.
    • Corticosteroids: Patients receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment
    • Myelosuppressive systemic therapy: At least 21 days must have elapsed after the last systemic myelosuppressive therapy.
    • Surgery: At least 6 weeks must have elapsed since major or intermediate surgery. Major surgery includes major craniotomy for tumor resection of cyst fenestration, organ resection, and exploratory laparotomy. Intermediate procedures include ventriculoperitoneal shunt placement, stereotactic brain biopsy, and intraventricular catheter placement. Minor procedures that are not excluded include skin biopsy/incision and drainage, bone marrow aspirate, and central venous catheter placement, ommaya aspirations, lumbar punctures, and nasal endoscopy to remove packing.
  6. Organ Function Requirements

    Adequate Bone Marrow Function Defined as:

    • Peripheral absolute neutrophil count (ANC) ≥1000/mm3
    • Platelet count ≥100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
    • Hemoglobin >8 g/dL (may be transfused)

    Adequate Renal Function Defined as:

    • Creatinine clearance or radioisotope GFR > 70ml/min/1.73 m2 or
    • A serum creatinine based on (Schwartz et al. J. Peds, 106:522, 1985) age/gender as follows:

      1. to < 2 years: maximum serum creatinine 0.6 mg/dL for males and females. 2 to < 6 years: maximum serum creatinine 0.8 mg/dL for males and females. 6 to < 10 years: maximum serum creatinine 1.0 mg/dL for males and females. 10 to < 13 years: maximum serum creatinine 1.2 mg/dL for males and females. 13 to < 16 years: maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females. ≥ 16 years: maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females.

    Adequate Liver Function Defined as:

    • Total bilirubin ≤ 1.5 × institutional upper limit of normal
    • AST (SGOT) ≤ 2.5 × institutional upper limit of normal
    • ALT (SGPT) ≤ 2.5 × institutional upper limit of normal

    Adequate Cardiac Function Defined as:

    • Left Ventricular Ejection Fraction greater than the institutional lower limit of normal by echocardiogram
    • QTc ≤ 480 msec (by Bazett formula)

    Adequate Neurologic Function Defined as:

    • Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.
    • Patients with current seizure disorders may be enrolled if seizures are well-controlled on antiepileptic therapies.
  7. Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines

Exclusion Criteria

  1. Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for at least 90 days after discontinuation of drug for females and at least 60 days for males. For females of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices; hormonal contraceptive methods must be supplemented by a barrier method) and agreement to refrain from donating eggs are required. For males of reproductive potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
  2. Gastrointestinal Disease:
    • Patients with a history of serious gastrointestinal disease, including inflammatory bowel disease or gastrointestinal perforation
    • Patients who are unable to swallow, retain or absorb oral medications
  3. Concomitant Medications
    • Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.
    • Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
    • Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible.
  4. Study Specific:
    • Patients who have an uncontrolled infection are not eligible.
    • Patients who have received any live or attenuated vaccinations within three months prior to start of therapy are not eligible.
    • Any significant concurrent medical or surgical condition that would jeopardize the patient's safety or ability to complete the study, including, but not limited to, disease of the nervous, renal, hepatic, cardiac (such as symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia), pulmonary, or endocrine system
    • Patients who have a history of Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus or Tuberculosis infection are not eligible.
    • Patients who have received a prior solid organ transplantation are not eligible.
    • Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
    • Patients who have a history of alcohol, drug, or chemical abuse within 6 months of screening.
    • Patients who have had surgery within the last 6 weeks or who have concerns for poor postsurgical wound healing.
    • Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to tocilizumab and its excipients are not eligible.

More Information

To learn more visit: https://clinicaltrials.gov/study/NCT05286788.


Esta página fue actualizada por última vez en: junio 16, 2025 09:16 a. m.

Ranked by U.S. News & World Report Among the Best Children's Hospitals.
Recognized by Newsweek as a world's best specialized hospital.
Leapfrog Top Hospital Award for Outstanding Quality and Safety.
Your local children's miracle network hospital.
Facebook Tik Tok Instagram YouTube
EmailSuscríbete al boletín DonateDonaciones

3100 S.W. 62nd Ave Miami, FL 33155

Número de teléfono: +1(305)666-6511
Para llamar sin cargo: +1(800)432-6837
Hospital principal

3100 S.W. 62nd Ave Miami, FL 33155

Número de teléfono: +1(305)666-6511
Para llamar sin cargo: +1(800)432-6837
Servicios médicos
  • Servicios médicos
  • Instituto del Cerebro
  • Instituto de Cáncer y Trastornos de la Sangre
  • Instituto del Corazón
  • Instituto de Ortopedia, Medicina Deportiva y la Columna Vertebral
  • Salud Deportiva
Ubicaciones
  • Ubicaciones
  • Centros de cuidados urgentes
  • Centros de cuidados ambulatorios
  • Centros de cuidados pediátricos
  • Centros de cuidados especializados
Recursos para pacientes
  • Recursos para pacientes
  • Pague su cuenta
  • Seguros médicos aceptados
  • Servicios financieros
  • Registros médicos
  • Transparencia de Precios
  • Verificador de Síntomas
Sobre nosotros
  • Sobre nosotros
  • Nuestra misión, visión, y valores
  • ¿Cómo puedo ayudar?
  • Sistema de salud
  • Fundación
  • Noticias y eventos
  • Directorio telefónico
Portales
  • Miembros de la junta
  • Empleados y médicos
  • Comité médico ejecutivo
  • Portal de vendedores
  • Portal del paciente
Servicios Lingüísticos
  • Servicios Lingüísticos
  • عربي | 中国人 | Français | Deutsch | Ελληνικά | Kreyòl Ayisyen | עברית | हिंदी | Italiano | 한국어 | Polski | Português | Русский | Español | ไทย | Tiếng Việt |
Information in English
Accesibilidad y Facilidad de Uso
Prácticas de Privacidad
Aviso Legal
Florida Health Finder
Requisitos de uso de mascarillas

© 2025 Nicklaus Children's Hospital. All Rights Reserved.